BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro

This publication has 26 references indexed in Scilit:

• The main function of IL-2 is to promote the development of T regulatory cells
  Journal of Leukocyte Biology, 2003
• A Randomized, Double‐Blinded, Placebo‐Controlled Trial of Intermittent Administration of Interleukin‐2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus
  The Journal of Infectious Diseases, 2003
• Interleukin 2 Leads to Dose-Dependent Expression of the Alpha Chain of the IL-2 Receptor on CD25-Negative T Lymphocytes in the Absence of Exogenous Antigenic Stimulation
  Clinical Immunology, 2000
• A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection
  The Journal of Infectious Diseases, 1999
• Antigen-independent activation of naive and memory resting T cells by a cytokine combination.
  The Journal of Experimental Medicine, 1994
• Tumor Necrosis Factor-α Plays a Central Role in Interleukin-2-Induced Pulmonary Vascular Leak and Lymphocyte Accumulation
  Cellular Immunology, 1994
• Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation
  Nature, 1994
• Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study
  European Journal of Cancer and Clinical Oncology, 1991
• Interleukin-2 Induces Early Multisystem Organ Edema Mediated by Neutrophils
  Annals of Surgery, 1991
• Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia.
  The Journal of Experimental Medicine, 1989